ST Pharm to Host RISC 2026...Discussing the Future of RNA Therapeutics

Leading Global Scholars and Industry Experts in RNA to Participate

ST Pharm announced on August 18 that it will hold the international symposium "RISC 2026" for RNA (ribonucleic acid) innovation on the 8th of next month at EL Tower in Yangjae, Seocho-gu, Seoul.

RISC is a symposium hosted by ST Pharm, aimed at sharing the latest research achievements and industry trends in the field of RNA therapeutics, while expanding global academic–industry–research collaboration. Following its inaugural event in 2024, this year marks the symposium's second edition.

ST Pharm will host the international symposium "RISC 2026" for RNA (ribonucleic acid) innovation on the 8th of next month at El Tower in Yangjae, Seocho-gu, Seoul. ST Pharm

This year’s event will feature leading international scholars and experts who have pioneered the global RNA therapeutics industry, including Professor Craig Mello of the University of Massachusetts, USA, who was awarded the 2006 Nobel Prize in Physiology or Medicine for his research in RNA interference (RNAi).

The symposium will provide updates on the latest research achievements and technological trends in next-generation RNA therapeutics, including messenger RNA (mRNA), antisense oligonucleotides (ASO), and small interfering RNA (siRNA). In addition to presentations by key speakers, there will be in-depth discussions on the future direction of R&D and the industrialization of RNA therapeutics.

A representative from ST Pharm emphasized, "As a global contract development and manufacturing organization (CDMO) specializing in RNA, ST Pharm will continue to strengthen its R&D and production capabilities, and contribute to the expansion of the global RNA open innovation ecosystem through networking events such as RISC."

This content was produced with the assistance of AI translation services.